88 related articles for article (PubMed ID: 22164405)
1. [Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats].
Reznikov OH; Chaĭkovs'ka LV; Poliakova LI; Sachyns'ka OV
Fiziol Zh (1994); 2011; 57(4):12-20. PubMed ID: 22164405
[TBL] [Abstract][Full Text] [Related]
2. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI; Grygorenko VN
Exp Oncol; 2011 Dec; 33(4):231-4. PubMed ID: 22217713
[TBL] [Abstract][Full Text] [Related]
3. [Nucleic acid and protein content in rat prostate during combined treatment with the gonadorelin agonist and an androgen receptor inhibitor].
Sachyns'ka OV
Fiziol Zh (1994); 2001; 47(6):30-4. PubMed ID: 11962088
[TBL] [Abstract][Full Text] [Related]
4. Nonsteroid antiandrogen inhibiting effect on testosterone metabolism in rat prostate and liver.
Reznikov A; Korpacheva T
Endocrinol Exp; 1990 Dec; 24(4):437-47. PubMed ID: 2096078
[TBL] [Abstract][Full Text] [Related]
5. [Effect of combined application of the synthetic luteinizing hormone-releasing hormone agonist and nonsteroidal antiandrogen on the reproductive system of male rats].
Sachyns'ka OV; Chaĭkovs'ka LV; Reznikov OH
Fiziol Zh (1994); 2006; 52(6):25-9. PubMed ID: 17333619
[TBL] [Abstract][Full Text] [Related]
6. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the rodent Hershberger bioassay: testing of coded chemicals and supplementary molecular-biological and biochemical investigations.
Freyberger A; Ellinger-Ziegelbauer H; Krötlinger F
Toxicology; 2007 Sep; 239(1-2):77-88. PubMed ID: 17688994
[TBL] [Abstract][Full Text] [Related]
8. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
9. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
10. [Nonsteroidal antiandrogen inhibition of testosterone metabolism in the prostate].
Reznikov AG; Korpacheva TI
Probl Endokrinol (Mosk); 1988; 34(2):64-7. PubMed ID: 3393507
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the expression of protein kinase C isoenzymes in rat ventral prostate: effects of age, castration and flutamide treatment.
Montalvo L; Sánchez-Chapado M; Prieto JC; Carmena MJ
Life Sci; 2002 Sep; 71(19):2257-66. PubMed ID: 12215373
[TBL] [Abstract][Full Text] [Related]
12. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
[TBL] [Abstract][Full Text] [Related]
14. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback.
Lund TD; Munson DJ; Haldy ME; Setchell KD; Lephart ED; Handa RJ
Biol Reprod; 2004 Apr; 70(4):1188-95. PubMed ID: 14681200
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antiandrogenic effects of flutamide, DDE, and linuron in the weanling rat assay using organ weight, histopathological, and proteomic approaches.
Tinwell H; Friry-Santini C; Rouquié D; Belluco S; Elies L; Pallen C; Bars R
Toxicol Sci; 2007 Nov; 100(1):54-65. PubMed ID: 17686919
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prostate gene expression and tissue weight changes as monitors of antiandrogen activity in GNRH-inhibited rats.
Nellemann C; Lefevre PA; Ashby J
Birth Defects Res B Dev Reprod Toxicol; 2003 Aug; 68(4):344-54. PubMed ID: 14666997
[TBL] [Abstract][Full Text] [Related]
18. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
[TBL] [Abstract][Full Text] [Related]
19. Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.
Brandes LJ; Queen GM; LaBella FS
Clin Cancer Res; 1997 Aug; 3(8):1357-61. PubMed ID: 9815819
[TBL] [Abstract][Full Text] [Related]
20. Effect of flutamide-induced androgen-receptor blockade on adenylate cyclase activation through G-protein coupled receptors in rat prostate.
Montalvo L; Carmena MJ; Solano RM; Clemente C; Román ID; Sánchez-Chapado M; Prieto JC
Cell Signal; 2000 May; 12(5):311-6. PubMed ID: 10822172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
